Drug Safety

, Volume 25, Issue 12, pp 885–892

Risk Management Strategies in the Physicians’ Desk Reference Product Labels for Pregnancy Category X Drugs

  • Kathleen Uhl
  • Dianne L. Kennedy
  • Sandra L. Kweder
Original Research Article

Abstract

Background: Drugs that carry a concern for teratogenicity are often classified as pregnancy category X in the drug label and contraindicated for use during pregnancy. Many drug labels can be found in the Physicians’ Desk Reference (PDR), a widely used source of drug information by American clinicians and patients.

Objective: To review product labelling in the electronic PDR for the pregnancy category X products for pregnancy prevention risk management components in labelling.

Methods: The electronic version of the 2001 and 2002 PDR was searched for ‘pregnancy category X’ products using the full text search feature. All product labels identified were retrieved and reviewed for trade name, generic name, manufacturer and indication. Product labels were manually searched for any pregnancy prevention risk management strategies included in labelling. Those labels that had specific pregnancy prevention risk management strategies were further evaluated.

Results: One hundred and seventeen pregnancy category X products were obtained from 2249 products searched in the 2001 PDR database and 124 pregnancy category X products were obtained from the 2150 products in the 2002 PDR database. All pregnancy category X products identified were drug products. The label/package insert for each drug was reviewed to identify risk management strategies for pregnancy prevention. The majority of the labels include as the sole risk management strategy either a black box warning and/or a contraindication for use in women who are or may become pregnant. Only 13 drugs contained specific pregnancy prevention risk management strategies in the label directing the clinician and/or patient, e.g. frequency of pregnancy testing, number and type of contraception methods. Two drugs, bexarotene capsules and gel, were only included in the 2001 PDR. Three drugs, isotretinoin, acitretin, and thalidomide, have formal pregnancy prevention risk management programmes.

Conclusion: This study demonstrates the varied risk management approaches in labelling for pregnancy prevention for pregnancy category X drugs. There is a need for consistency in the classification of pregnancy category X products and the pregnancy prevention risk management strategies utilised in the labelling for them.

References

  1. 1.
    Pregnancy labeling. FDA Drug Bull 1979; 9 (4): 23–4Google Scholar
  2. 2.
    Weiss S, Vega A, McCloskey C, et al. Drug use in pregnancy: prescription drug use during pregnancy among women in Kaiser Permanente Northwest, 1993-1994. Report to the Office of Women’s Health, US FDA, 1997 Oct 7Google Scholar
  3. 3.
    Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet 2000 Nov; 356(9243): 1735–6PubMedCrossRefGoogle Scholar
  4. 4.
    Olesen C, Sorensen HT, Jong-Van Den Berg LD, et al. Prescribing during pregnancy and lactation with reference to the Swedish classification system: a populations-based study among Danish women. Acta Obstet Gynecol Scand 1999 Sep; 78(8): 686–92PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen JS, Insel PA. The Physicians’ Desk Reference: problems and possible improvements. Arch Intern Med 1996 Jul; 156(13): 1375–80PubMedCrossRefGoogle Scholar
  6. 6.
    Hatton RC, Doering PL, Frias JL. Physicians’ sources of information about teratogenic effects of drugs. Drug Inf J 1982 Jul–Sep; 16(3): 148–53PubMedGoogle Scholar
  7. 7.
    Physicians’ Desk Reference. Suppl. B. 55th ed.Montvale (NJ): Medical Economics Company Inc, 2001Google Scholar
  8. 8.
    Friedman JM, Polifka JE. Teratogenic effects of drugs: a resource for clinicians (TERIS). 2nd ed. Baltimore (MD): The Johns Hopkins University Press, 2000Google Scholar
  9. 9.
    Scialli AR. A clinical guide to reproductive and development toxicology. Boca Raton (FL): CRC Press Inc, 1992Google Scholar
  10. 10.
    Sanz E, Gomes-Lopez T, Martinez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 2001 Mar; 95(1): 127–31PubMedCrossRefGoogle Scholar
  11. 11.
    Koren G, Bologa M, Long D, et al. Perception of teratogenic risk by pregnant women exposed to drugs and chemical during the first trimester. Am J Obstet Gynecol 1989 Aug; 160(5 Pt 1): 1190–204PubMedGoogle Scholar
  12. 12.
    Department of Health and Human Services, Food and Drug Administration. Requirements on content and format of labeling for human prescription drugs and biologics: requirements for prescription drug product labels. Fed Regist 2000 Dec; 65 (247): 81082–131Google Scholar
  13. 13.
    Department of Health and Human Services, Food and Drug Administration (FDA). Content and format of labeling for human prescription drugs, pregnancy labeling, public hearing–FDA: notice of public hearing, request for comments. Fed Regist 1997; 62: 41061–3Google Scholar
  14. 14.
    Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother 2001 Nov; 35(11): 1485–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Kathleen Uhl
    • 1
  • Dianne L. Kennedy
    • 1
  • Sandra L. Kweder
    • 1
  1. 1.US Food and Drug AdministrationCenter for Drug Evaluation and Research, Office of New Drugs, Pregnancy Labeling TeamRockvilleUSA

Personalised recommendations